Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medical Device Market & Industry Briefs, September 2012

Executive Summary

Brief summaries of recent medtech market and industry developments. This month we cover results of St. Jude’s FAME II fractional flow reserve trial, a breakthrough technology for treating vascular occlusions, and analysis from START-UP magazine’s second annual Life Science Venture Capital Survey.

Advertisement

Related Content

Obesity Intervention: A New Era Of Discovery And Innovation
Obesity Intervention: A New Era Of Discovery And Innovation
The Renal Denervation Buzz: Separating Fact From Myth; Covidien Buys Maya Medical
Covidien Acquisitions Keeps Buying Spree Alive
Fractional Flow Reserve Makes Inroads In Interventional Cardiology
Fractional Flow Reserve Proves Itself Early In St. Jude’s FAME II Study
Ascension Rises: Hospital Venture Group Gets More Muscle
COURAGE Suggests Stents Do Not Benefit Stable Coronary Disease Patients

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

MT035554

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel